Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients

• Status: Unknown status
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to investigate the efficacy and safety of Folfox4 chemotherapy regimen to prevent early recurrence for hepatocellular carcinoma patients with portal vein tumor thrombus following curative resection

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangxi Medical University

Criteria

Inclusion Criteria:

• patients undergo curative resection

• HCC with PVTT is confirmed by pathological examination

• patients undergo chemotherapy of Folfox4 regimen

• patients without recurrence within the first month after curative resection

• residual hepatic function is Child-pugh A or B which is capable to tolerate chemotherapy

• patients without other postoperative adjuvant treatments including TACE, radiotherapy, immunotherapy

Exclusion Criteria:

• Multipal intra-hepatic or outra-hepatic tastasis within the first month after curative resection

• patients with residual hepatic function Child-pugh C is not capable to tolerate chemotherapy

• patients undergo postoperative adjuvant treatments except chemotherapy of Folfox4 regimen

• patients with badly chemotherapy complications who can finish the whole Folfox4 treatment course